Johnson & Johnson Reports Soaring Financial Results

By Chris Stiles • Wednesday, January 21 10:48 • Permanent Link

Johnson & Johnson (J&J) has reported strong financial results for the fourth quarter and full year of 2025. In the fourth quarter, reported sales grew by 9.1% to $24.6 billion, with operational growth at 7.1% and adjusted operational growth at 6.1%. The company's net earnings for the quarter surged by 49.1% to $5.116 billion, and earnings per share (EPS) grew by 48.9% to $2.10.

For the full year of 2025, reported sales increased by 6.0% to $94.2 billion, with operational growth at 5.3% and adjusted operational growth at 4.2%. Net earnings for the full year soared by 90.6% to $26.804 billion, and EPS grew by 90.5% to $11.03.

Looking at non-GAAP measures, adjusted net earnings for the full year of 2025 increased by 21.5% to $6.009 billion, and adjusted EPS (diluted) grew by 20.6% to $2.46.

In terms of regional sales, the U.S. market saw reported sales growth of 7.5% in the fourth quarter, while international markets experienced reported sales growth of 11.3%. For the full year, the U.S. market reported sales growth of 6.9%, and international markets reported sales growth of 5.0%.

Breaking down segment sales, the Innovative Medicine segment reported a 10.0% increase in sales for the fourth quarter and a 6.0% increase for the full year, while the MedTech segment reported a 7.5% increase in sales for the fourth quarter and a 6.1% increase for the full year.

J&J also provided guidance for 2026, estimating reported sales of $100.5 billion, representing a 6.7% increase at the midpoint, and adjusted EPS of $11.53, a 6.9% increase at the midpoint.

The company's significant achievements in 2025 include the approvals of Caplyta for major depressive disorder and Rybrevant Faspro plus Lazcluze for non-small cell lung cancer, as well as landmark data for Tecvayli plus Darzalex Faspro as a potential standard of care for patients with relapsed/refractory multiple myeloma.

These financial and operational results demonstrate a strong performance for Johnson & Johnson in 2025, driven by robust sales growth, earnings, and significant innovation across its business segments. The market has reacted to these announcements by moving the company's shares -0.41% to a price of $218.66. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.